18:46 , Sep 7, 2018 |  BioCentury  |  Emerging Company Profile

Leveraging cross-linking

Lyvgen Biopharma Co. Ltd. is using its xLinkAb platform to develop mAbs that agonize T cell or dendritic cell co-stimulatory receptors with better safety and selectivity for tumors than competing mAbs. According to founder and...
16:57 , Jul 20, 2018 |  BC Week In Review  |  Financial News

6 Dimensions leads Lyvgen's $30M series B

Lyvgen Biopharma Co. Ltd. (Shanghai, China) raised $30 million in a series B round led by 6 Dimensions Capital. New investors Winfair Global and Runling Capital and existing investor Morningside Ventures also participated. Lyvgen is...
22:56 , Jul 16, 2018 |  BC Extra  |  Financial News

6 Dimensions leads Lyvgen's $30M series B

Lyvgen Biopharma Co. Ltd. (Shanghai, China) raised $30 million in a series B round led by 6 Dimensions Capital. New investors Winfair Global and Runling Capital and existing investor Morningside Ventures also participated. Lyvgen is...